Cancer is a highly complex disease. Historically, cancer has been named after the organ of origin of the tumor; and most cancers are retaining specific characteristics of this origin. But looking at the molecular level, many cancers look alike and major cancer pathways are active (or can be activated) in all cancer types. For example, two breast cancers can be more different at the molecular level (and then in term of therapy regimen) than a breast cancer and an ovarian cancer can be. That’s why OncoDEEP is looking, in a non-supervised way, to more than 60 cancer actionable genes.
When oncologists order an OncoDEEP testing for the first time, it’s usually related to patients who have already received treatments from guidelines and which have failed; the same guidelines that are only requiring single gene testing for the prescription of an approved drug for a specific cancer type. For those patients, OncoDEEP has now so many times demonstrated that a) those failed guidelines could have been detected earlier, speeding up the choice of the right treatment by a closer observation of suspected failure; b) in many complex cancer cases, those “single gene” or “specific pathway” are not always enough to fully characterize the patients and provide them with the most efficient treatment.
Using OncoDEEP is providing the most cost-effective molecular characterization of the tumor of the patient and by doing so, taking stock of the prescription portfolio available, not just the drugs that are approved (because if those are often enough, it’s not always the case) but also for those which are approved for other indications or those which are still under development (and have already proven their efficacy in these trials). These last two opportunities are sometimes the only potentially efficient treatment for a patient with complex cancer and you can’t find them just looking at “specific pathway”.
The interest of Oncotype DX® Breast Cancer Assays related to treatment only concerns ER-positive, HER2-negative invasive breast cancer patients. The test calculates a risk score, based on gene expression profiling, to help determine the magnitude of tamoxifen benefit for an individual patient. As it is a statistical score based on gene signature, the assay needs to be validated in a validation clinical study.
OncoDEEP questions both genetic variants (using Next Generation Sequencing) and protein biomarkers (using molecular pathology tests) and is not just specific to breast cancer or specific to a single breast cancer subtype but can address all breast cancers and other cancer types with solid tumors (Lung, Glioma, Colorectal, ….). It helps determine treatment options amongst all available cancer drugs based on the comprehensive molecular characterization of the tumor. Conclusions delivered by OncoDEEP are relying only on strong clinical trial evidence for each marker.
MammaPrint is the first FDA-cleared assay that tests for breast cancer recurrence rates. So it measures the risk of distant recurrence following surgery. For assistance in their therapeutic decision making, and as mentioned on Agendia’s website, physicians will need other clinical criteria and pathology tests to be performed…
OncoDEEP does not measure any risk of recurrence. Its only goal is to help physicians with treatment options proposals based on a complete molecular characterization of the tumor of the patient. OncoDEEP is expert in helping physicians with therapeutic decisions.
The price depends on the test you have selected. The simplest way to proceed to payment is using credit card payment. You may also pay by wire transfer using these Bank Account Information.
25,Avenue George Lemaître
BELGIUM - EUROPE
IBAN : BE72 3631 1253 7016
BIC : BBRUBEBB
We are working with local agent/distributor who are visiting physician/oncologist to increasing awareness about OncoDEEP/OncoSHARE. If you’re a healthcare professional and have questions in relationship with OncoDEEP distribution, feel free to tell us and we will put you in contact with your local distributor.